Merck
CN

Viral Vector Upstream Platforms

Optimizing the upstream portion of gene therapy production sets the stage for successful manufacturing by maximizing viral vector titers. To increase upstream titers and reduce variability and risk, manufacturers must partner with upstream technology experts who work with HEK293, HEK293T and Sf9 cells.

Gene therapies in the market today use viral vectors to introduce modified genetic material into targeted cells. This means gene therapy manufacturing starts with the upstream production of vectors either through transient transfection or use of stable producer cell line which culminates in the harvesting of the viral vector produced. This feeds into downstream purification and concentration to ensure the product has high efficacy and safety to pass regulatory requirements. Therefore, making the right upstream process decisions not only impacts immediate upstream outputs, but also downstream processes, timelines and regulatory acceptance.

Four major challenges that face upstream manufacturing today include: High productivity, process robustness, scalability for commercial production, and product quality. Using optimized, time-effective upstream production platforms can help gene therapy manufacturers address key upstream challenges. Draw on our experience to learn how you can speed your gene therapy to patients.


Lentivirus Manufacturing:

Are you looking for a platform that achieves best-in-class performance for lentivirus production?

  • The VirusExpress® 293T Lentiviral Production Platform offers a transfection-based solution to lentiviral (LV) production challenges, featuring a suspension adapted cell line, chemically defined medium, and process with proven performance at 50 L scale.

Adeno-associated Virus (AAV) Manufacturing:

Are you an AAV manufacturer looking for a high quality, high performance upstream platform?

  • The VirusExpress® 293 AAV Production Platform offers a transfection-based solution using a suspension adapted cell line, chemically defined medium, and a clinically relevant process dramatically reducing time to production.
  • Sf9 Rhabdovirus-Negative (Sf-RVN®) Platform provides a rhabdovirus-free cell line that improves the safety profile of your bioprocesses combined with a chemically defined medium specifically formulated to get excellent growth and productivity while adhering to regulatory requirements.

Related Product Resources


VirusExpress® 293T Lentiviral Production Cells combined with EX-CELL® CD HEK293 Viral Vector Media forms the VirusExpress® 293T Lentiviral Production Platform, helping to reduce time in process development and scale-up.

THE VIRUSEXPRESS® 293T LENTIVIRAL PRODUCTION PLATFORM

The VirusExpress® 293T Lentiviral Production Platform offers a transfection-based solution to LV production challenges, featuring a suspension adapted cell line, chemically defined medium, and process with proven performance at 50 L scale. The platform can dramatically reduce time in process development and scale-up, either within your own facilities or using our contract manufacturing capabilities to speed your therapy to patients.

Key Advantages of VirusExpress® 293T Lentiviral Production Platform Include:

VirusExpress® 293T Lentiviral Production Cells

  • Cell line grows to high cell density and viability in suspension and has lower doubling time
  • Selected for higher lentivirus production using PEI-based transient transfection method
  • GMP-banked and fully characterized HEK 293T cells
  • Fully traceable and documentation available for regulatory filings
  • Licenses available for research or clinical/commercial use

EX-CELL® CD HEK293 Viral Vector Medium

  • Chemically defined, animal component-free cell culture medium
  • Supports high cell density and faster growth of HEK293T cells
  • Compatible with the PEI based transfection reagents used for viral production
  • No need for addition of boost and enhancer reagents for transfection step
  • Available in liquid and dry powder formats

Proven Process

  • Upstream production process optimized and demonstrated for performance from shake flasks to 50L bioreactor
  • Downstream process developed for purification of lentivirus at clinically relevant scale
  • Up to 40% reduction in process development and scale-up time

VirusExpress® 293T Lentiviral Production Platform Performance


VirusExpress® 293 AAV Production Cells combined with EX-CELL® CD HEK293 Viral Vector Media forms the VirusExpress® 293 AAV Production Platform, offering a higher vector yield than adherent platforms and a simpler process than competitor products.

THE VIRUSEXPRESS® 293 AAV PRODUCTION PLATFORM

The VirusExpress® 293 AAV Production Platform offers a transfection-based solution using a HEK293 suspension adapted cell line, chemically defined medium, and a clinically relevant process dramatically reducing time to commercial production. The VirusExpress® Production Platform offers a higher vector yield than adherent platforms and a simpler process than competitor products. The VirusExpress® Production Platform has been optimized for AAV2, AAV5, AAV6 and other serotype production.

Key Advantages of VirusExpress® 293 AAV Production Platform Include:

VirusExpress® 293 AAV Production Cells

  • Cell line grows to high cell density and viability in suspension and has lower doubling time
  • Selected for higher rAAV production using PEI-based transient transfection method
  • GMP-banked and fully characterized HEK 293 cells
  • Fully traceable and documentation available for regulatory filings
  • Licenses available for research or clinical/commercial use

EX-CELL® CD HEK293 Viral Vector Medium

  • Chemically defined, animal component-free cell culture medium
  • Supports high cell density and faster growth of HEK293 cells
  • Compatible with the PEI based transfection reagents used for AAV production
  • No need for addition of boost and enhancer reagents for transfection step
  • Available in liquid and dry powder formats

Proven Process

  • Upstream production process optimized and demonstrated for performance from shake flasks to 50L bioreactor
  • Downstream process developed for purification of AAV at clinically relevant scale
  • Up to 40% reduction in process development and scale-up time

VirusExpress® 293 AAV Production Platform Performance


The Sf-RVN® Insect Cell Line offers a rhabdovirus-free alternative and enhances risk mitigation. Together with the chemically defined medium, EX-CELL® CD Insect Cell Medium, forms the Sf-RVN® Platform, providing a high-performance platform optimal to produce adeno-associated vectors (AAV) for gene therapy applications.

THE Sf-RVN® PLATFORM

For Improving the Safety Profile of Your Baculovirus-Insect Cell Based Vaccines and Gene Therapies

The Sf-RVN® Insect Cell Line offers a rhabdovirus-free alternative and enhances risk mitigation. Together with the chemically defined medium, EX-CELL® CD Insect Cell Medium, forms the Sf-RVN® Platform, providing a high-performance platform optimal to produce adeno-associated vectors (AAV) for gene therapy applications.

Key Advantages of the Sf-RVN® Platform include

Sf-RVN® Insect Cell Line

  • Sf9 rhabdovirus-negative cell line
  • Adventitious agent tested and GMP banked in EX-CELL® CD Insect Cell Medium
  • Full traceability and documentation available for regulatory filings

EX-CELL® CD Insect Cell Medium

  • Chemically defined and animal component free
  • High reproducibility and lot-to-lot reliability
  • Supports growth of multiple insect cell lines
  • Optimized for the Sf-RVN® Insect Cell Line
  • Available in liquid and dry powdered medium

Benefits

  • Improved Safety - Enhanced risk mitigation with the rhabdovirus negative cell line
  • High Performance - Optimized to get high low doubling time, high cell viability and high AAV titer
  • Flexible Options - Several license agreement options available
  • Technical Support - Technical user guide with detailed protocols for optimal performances

Related Products
Loading




Highlights


Request Information

If interested in any of our upstream platforms above, please complete and submit the webform below for more information and begin bringing your gene therapy to life.

Fields indicated by a * are mandatory.


 

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?